RESULTS: OSTEOPLANT ANGIOSTAD preserved MSC’s viability and improved their capacity to release TGF-b1. It also increased in vitro wound healing by MSC and migration of endothelial cells.
CONCLUSION: The results show that, since it increases the production by MSC of proangiogenic factors such as TGF-beta and promotes endothelial cell migration, OSTEOPLANT ANGIOSTAD may be an appropriate adjunct to accelerate the osteointegration of bone substitutes.
Sede Amministrativa e legale
via E. Fermi, 49
36057 Arcugnano, Vicenza (VI) - Italia
Tel. +39 0444 289366
Fax: +39 0444 285272
Centro Polifunzionale di produzione
Via G. Agnelli, 3
10020 Riva presso Chieri, Torino (TO) - Italia